Moleculin Biotech, Inc. (MBRX)
Score window: Apr. 15, 2025 to Apr. 14, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Jan. 2, 2026 | CORRESP | Neutral/Informational | Moderate | Moleculin Biotech, Inc. has submitted a request to the SEC to accelerate the effective date of their Registration Statement on Form S-1. They are seeking to have it declared effec… | Read Filing EDGAR |
| Jan. 2, 2026 | UPLOAD | Neutral/Informational | Low | The SEC has notified Moleculin Biotech, Inc. that it will not review their registration statement filed on December 23, 2025. The letter emphasizes that the responsibility for the… | Read Filing EDGAR |
| Sep. 29, 2025 | CORRESP | Neutral/Informational | Moderate | Moleculin Biotech, Inc. has submitted a request to the SEC to accelerate the effective date of their Registration Statement on Form S-3. They are seeking to have it declared effec… | Read Filing EDGAR |
| Sep. 24, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to Moleculin Biotech, Inc. that it will not review the company's registration statement filed on September 19, 2025. The SEC emphasizes that the responsib… | Read Filing EDGAR |
| Jun. 17, 2025 | CORRESP | Neutral/Informational | Moderate | The correspondence from Roth Capital Partners, LLC, serves as a formal concurrence to Moleculin Biotech, Inc.'s request for the acceleration of the effective date of their registr… | Read Filing EDGAR |
| Jun. 17, 2025 | CORRESP | Neutral/Informational | Moderate | Moleculin Biotech, Inc. has submitted a request to the SEC to accelerate the effective date of their Registration Statement on Form S-1. They are seeking to have it declared effec… | Read Filing EDGAR |
| Jun. 16, 2025 | CORRESP | Concern from SEC | Moderate | Moleculin Biotech, Inc. submitted a response to the SEC's comment letter regarding their Amendment No. 2 to Registration Statement on Form S-1. The SEC raised concerns about poten… | Read Filing EDGAR |
| Jun. 13, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed Moleculin Biotech, Inc.'s amended registration statement and provided several comments that require the company's attention. Key concerns include the need for… | Read Filing EDGAR |
| Jun. 11, 2025 | CORRESP | Concern from SEC | Moderate | Moleculin Biotech, Inc. submitted a response to the SEC's comment letter regarding their Amendment No. 1 to Registration Statement on Form S-1. The SEC raised concerns about the p… | Read Filing EDGAR |
| Jun. 10, 2025 | UPLOAD | Concern from SEC | Moderate | The SEC has reviewed Moleculin Biotech, Inc.'s amended registration statement and provided comments that require the company to revise certain disclosures. Specifically, the SEC i… | Read Filing EDGAR |
| Jun. 3, 2025 | CORRESP | Neutral/Informational | Moderate | Moleculin Biotech, Inc. has submitted a request to the SEC to accelerate the effective date of their Registration Statement on Form S-1. They are seeking to have it declared effec… | Read Filing EDGAR |
| Jun. 3, 2025 | CORRESP | Neutral/Informational | Moderate | The correspondence from Roth Capital Partners, LLC to the SEC concerns the acceleration request for the effective date of Moleculin Biotech, Inc.'s registration statement on Form … | Read Filing EDGAR |